Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion

EconomyDaily Composite

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

Source

CNBC

Read full article at CNBC

Opens original article in a new tab

Oil prices fall as Trump tries to convince market an Iran deal is close despite recent violence

President Donald Trump has repeatedly said a deal with Tehran to reopen Hormuz is close, but such an agreement still has not materialized.

18 minutes agoRead more →

EconomyDaily Composite

Yahoo Finance

Second Nature Brands enters meat snacks with Tillamook deal

21 minutes agoRead more →

EconomyDaily Composite

CNBC

The 'SaaSpocalypse' is over, says private equity giant Thoma Bravo. Here's why it sees an AI boom for software

Thoma Bravo founder Orlando Bravo says AI offers an "enormous tailwind" for software companies.

22 minutes agoRead more →

Bloomberg Markets

JPMorgan Sees Stocks Powering Through Any Short, Sharp Pullbacks

US stocks have further to run as corporate earnings growth underpins sentiment despite some signals suggesting equities may have risen too far, JPMorgan Asset Management’s Jack Caffrey said.

24 minutes agoRead more →

Related Economy Stories

Oil prices fall as Trump tries to convince market an Iran deal is close despite recent violence

Second Nature Brands enters meat snacks with Tillamook deal

The 'SaaSpocalypse' is over, says private equity giant Thoma Bravo. Here's why it sees an AI boom for software

JPMorgan Sees Stocks Powering Through Any Short, Sharp Pullbacks